1-3 of 3
Stacy Cooper, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw
Journal: Blood
Blood (2018) 132 (Supplement 1): 927.
https://doi.org/10.1182/blood-2018-99-111279
Published: 2018
Journal Articles

Pathways Relevant to AML Pathogenesis Targeting the Hematopoietic-Specific Cebpa +37 Kb Enhancer

Stacy Cooper, MD, Hong Guo, MD PhD, Justin Thomas, Jay L. Hess, MD PhD, Peter D. Aplan, MD, Donald Small, MD PhD, Alan D. Friedman, MD
Journal: Blood
Blood (2016) 128 (22): 2691.
https://doi.org/10.1182/blood.V128.22.2691.2691
Published: 2016
Journal Articles

In Vivo Deletion of the Cebpa +37 Kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis

Alan D. Friedman, MD, Hong Guo, MD PhD, Stacy Cooper, MD
Journal: Blood
Blood (2015) 126 (23): 1178.
https://doi.org/10.1182/blood.V126.23.1178.1178
Published: 2015